| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Venrock Healthcare Capital Partners III, L.P. | 3.8% | $51,436,214 | 2,047,620 | Venrock Healthcare Capital Partners III, L.P. | 30 Jun 2025 | |||
| Bain Capital Life Sciences Fund, L.P. | 2.5% | -17% | $41,020,425 | -$5,670,300 | 1,640,817 | -12% | Bain Capital Life Sciences Fund, L.P. | 31 Dec 2025 |
As of 31 Dec 2025, 104 institutional investors reported holding 58,984,858 shares of Pharvaris N.V. - Ordinary Shares, Euro 0.12 par value per share (PHVS). This represents 90% of the company’s total 65,632,680 outstanding shares.
The largest institutional shareholders of Pharvaris N.V. - Ordinary Shares, Euro 0.12 par value per share (PHVS) together control 80% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| GENERAL ATLANTIC, L.P. | 12% | 8,031,252 | 0% | 7.8% | $222,867,243 |
| FMR LLC | 9.7% | 6,399,158 | 0% | 0.01% | $177,576,635 |
| Foresite Capital Management IV, LLC | 7.3% | 4,778,581 | 0% | 58% | $132,605,623 |
| venBio Partners LLC | 7.1% | 4,639,304 | 0% | 60% | $128,740,686 |
| VIKING GLOBAL INVESTORS LP | 5.6% | 3,653,310 | 0% | 0.27% | $101,379,353 |
| EQT Fund Management S.a r.l. | 5.2% | 3,424,609 | 0% | 8.5% | $95,032,900 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 4.8% | 3,126,042 | +28% | 1.1% | $86,747,666 |
| Bain Capital Life Sciences Investors, LLC | 4.3% | 2,802,081 | -12% | 6% | $77,757,748 |
| WELLINGTON MANAGEMENT GROUP LLP | 2.9% | 1,905,793 | +9.9% | 0.01% | $52,885,757 |
| Commodore Capital LP | 2.9% | 1,889,445 | -22% | 3.5% | $52,432,099 |
| NOVO HOLDINGS A/S | 2.7% | 1,750,000 | 0% | 3.8% | $48,562,500 |
| Saturn V Capital Management LP | 1.7% | 1,140,033 | +29% | 5.8% | $31,635,916 |
| Cormorant Asset Management, LP | 1.7% | 1,083,000 | -21% | 1.7% | $30,053,250 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.4% | 941,605 | +15% | 0% | $26,130,000 |
| 5AM Venture Management, LLC | 1.2% | 797,600 | 0% | 7% | $22,133,400 |
| Sofinnova Investments, Inc. | 1.1% | 745,169 | +0.72% | 0.89% | $20,678,440 |
| Point72 Asset Management, L.P. | 1.1% | 711,625 | +37% | 0.03% | $19,747,594 |
| BlackRock, Inc. | 1.1% | 708,558 | +71% | 0% | $19,662,485 |
| Soleus Capital Management, L.P. | 1.1% | 702,052 | +8.5% | 0.83% | $19,481,943 |
| Octagon Capital Advisors LP | 1% | 671,465 | -7.1% | 2.3% | $18,633,154 |
| Kynam Capital Management, LP | 0.98% | 640,395 | -5.1% | 1.2% | $17,770,961 |
| Rock Springs Capital Management LP | 0.95% | 623,402 | 0% | 0.89% | $17,299,406 |
| Patient Square Capital LP | 0.83% | 542,696 | +57% | 3.2% | $15,059,814 |
| Balyasny Asset Management L.P. | 0.76% | 496,259 | -21% | 0.03% | $13,771,187 |
| Ikarian Capital, LLC | 0.74% | 486,856 | +132% | 1.8% | $13,510,255 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 58,984,858 | $1,636,472,561 | +$19,048,268 | $27.75 | 104 |
| 2025 Q3 | 57,844,608 | $1,443,142,875 | +$236,461,386 | $24.95 | 83 |
| 2025 Q2 | 45,040,180 | $792,712,813 | +$1,806,103 | $17.60 | 60 |
| 2025 Q1 | 44,939,067 | $705,543,867 | +$4,132,739 | $15.70 | 52 |
| 2024 Q4 | 44,644,168 | $855,824,077 | -$7,190,155 | $19.17 | 54 |
| 2024 Q3 | 45,045,428 | $834,243,398 | +$34,119,580 | $18.52 | 51 |
| 2024 Q2 | 43,008,763 | $808,565,649 | +$10,680,383 | $18.80 | 36 |
| 2024 Q1 | 42,425,740 | $980,459,437 | +$36,728,417 | $23.11 | 35 |
| 2023 Q4 | 40,745,703 | $1,142,917,292 | +$327,949,428 | $28.05 | 36 |
| 2023 Q3 | 29,067,102 | $606,630,419 | +$4,468,799 | $20.87 | 21 |
| 2023 Q2 | 28,913,752 | $441,577,880 | +$109,619,000 | $15.14 | 21 |
| 2023 Q1 | 21,781,494 | $173,888,454 | +$3,756,313 | $8.06 | 21 |
| 2022 Q4 | 21,301,855 | $239,644,411 | -$1,830,525 | $11.25 | 25 |
| 2022 Q3 | 22,314,954 | $173,600,000 | -$317,120 | $7.67 | 21 |
| 2022 Q2 | 22,353,338 | $494,009,000 | +$14,911,660 | $22.10 | 20 |
| 2022 Q1 | 21,685,388 | $397,090,000 | +$838,867 | $18.14 | 22 |
| 2021 Q4 | 21,647,018 | $321,068,000 | -$1,695,268 | $14.39 | 22 |
| 2021 Q3 | 21,631,638 | $380,302,000 | -$6,827,497 | $17.73 | 25 |
| 2021 Q2 | 21,995,815 | $406,288,000 | -$1,442,853 | $18.62 | 28 |
| 2021 Q1 | 22,025,122 | $616,507,000 | +$616,507,000 | $27.99 | 33 |